Left atrial blood stasis and von willebrand factor-adamts13 homeostasis in atrial fibrillation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 11, 2011, Pages 2760-2766

  Ammash, Naser ^a,b   Konik, Ewa A ^a,b   McBane, Robert D ^a,b   Chen, Dong ^a   Tange, Julie I ^a   Grill, Diane E ^a,b   Herges, Regina M ^a,b   McLeod, Thomas G ^a   Friedman, Paul A ^a,b   Wysokinski, Waldemar E ^a,b  

^a Department of Internal Medicine ^*  (United States)

^b MAYO CLINIC   (United States)

Author keywords

atrial fibrillation; stroke; thrombosis; von Willebrand factor

Indexed keywords

VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINUS RHYTHM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; VELOCITY;

ADAM PROTEINS; AGED; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; FEMALE; HEART ATRIA; HOMEOSTASIS; HUMANS; MALE; MIDDLE AGED; REGIONAL BLOOD FLOW; RISK FACTORS; THROMBOEMBOLISM; VON WILLEBRAND FACTOR;

EID: 80054925033     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.232991     Document Type: Article

References (39)

1. Aberg H. Atrial fibrillation: I: a study of atrial thrombosis and systemic embolism in a necropsy material. Acta Med Scand. 1969;185:373-379.
2. Manning WJ, Silverman DI, Waksmonski CA, Oettgen P, Douglas PS. Prevalence of residual left atrial thrombi among patients with acute thromboembolism and newly recognized atrial fibrillation. Arch Intern Med. 1995;155:2193-2198.
3. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, Davidoff R, Erbel R, Halperin JL, Orsinelli DA, Porter TR, Stoddard MF; Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation N Engl J Med. 2001;344:1411-1420. (Pubitemid 32402097)
4. Handke M, Harloff A, Hetzel A, Olschewski M, Bode C, Geibel A. Left atrial appendage flow velocity as a quantitative surrogate parameter for thromboembolic risk: determinants and relationship to spontaneous echocontrast and thrombus formation: a transesophageal echocardiographic study in 500 patients with cerebral ischemia. J Am Soc Echocardiogr. 2005;18:1366-1372. (Pubitemid 41821184)
5. Goldman ME, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Safford R, Halperin JL. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I: reduced flow velocity in the left atrial appendage (the Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr. 1999;12:1080-1087.
6. Bernhardt P, Schmidt H, Hammerstingl C, Lüderitz B, Omran H. Patients with atrial fibrillation and dense spontaneous echo contrast at high risk a prospective and serial follow-up over 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging. J Am Coll Cardiol. 2005;45:1813-1814.
7. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol. 1998;31: 1622-1626. (Pubitemid 28273307)
8. Ruggeri ZM, Savage B. Biological functions of von Willebrand factor. In: Ruggeri ZM, ed. Von Willebrand Factor and the Mechanisms of Platelet Function. Berlin, Germany: Springer; 1998:79-109.
9. Feinberg WM, Pearce LA, Hart RG, Cushman M. Cornell ES, Lip GY, Bovill EG. Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke. 1999;30:2547-2553.
10. Conway DSG, Pearce LA, Chin BS, Hart RG, Lip GY. Plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 1321 patients with non-valvular atrial fibrillation: relationship to stroke risk factors. Circulation. 2002;106: 1962-1967. (Pubitemid 35176302)
11. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation. 2003;107:3141-3145. (Pubitemid 36793082)
12. Watson T, Arya A, Sulke N, Lip GY. Relationship of indices of inflammation and thrombogenesis to arrhythmia burden in paroxysmal atrial fibrillation. Chest. 2010;137:869-876.
13. Uemura T, Kaikita K, Yamabe H, Soejima K, Matsukawa M, Fuchigami S, Tanaka Y, Morihisa K, Enomoto K, Sumida H, Sugiyama S, Ogawa H. Changes in plasma von Willebrand factor and ADAMTS13 levels associated with left atrial remodeling in atrial fibrillation. Thromb Res. 2009; 124:28-32.
14. Freestone B, Gustafsson F, Chong AY, Corell P, Kistorp C, Hildebrandt P, Lip GY. Influence of atrial fibrillation on plasma von Willebrand factor, soluble E-selectin, and N-terminal pro B-type natriuretic peptide levels in systolic heart failure. Chest. 2008;133:1203-1208. (Pubitemid 351685527)
15. Fu R, Wu S, Wu P, Qiu J. A study of blood soluble P-selectin, fibrinogen, and von Willebrand factor levels in idiopathic and lone atrial fibrillation. Europace. 2011;13:31-36.
16. Hou J, Liang Y, Gai X, Zhang H, Yang X, Lan X, Zheng W, Huang M. The impact of acute atrial fibrillation on the prothrombotic state in patients with essential hypertension. Clin Biochem. 2010;43:1212-1215.
17. Fischer BE, Thomas KB, Dorner F. Von Willebrand factor: measuring antigen or function? Correlation between the level of antigen, activity, and multimer size using various detection systems. Thromb Haemost. 1998;91:39-43. (Pubitemid 28376670)
18. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276:41059-41063.
19. Fukuchi M, Watanabe J, Kumagai K, Katori Y, Baba S, Fukuda K, Yagi T, Iguchi A, Yokoyama H, Miura M, Kagaya Y, Sato S, Tabayashi K, Shirato K. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol. 2001;37:1436-1442.
20. Lopez JA, Dong JF. Cleavage of von Willebrand factor by ADAMTS13 on endothelial cells. Semin Hematol. 2004;41:15-23. (Pubitemid 38057781)
21. Melduni RM, Chandrasekaran K, Friedman PA, White RD, Malouf JF, Hodge DO, Seward JB, Oh JK, Ammash NM. Does left atrial appendage peak emptying flow velocity predict the electrical energy required to achieve successful direct-current cardioversion in patients with persistent atrial fibrillation? J Am Soc Echocardiogr. 2007;20:1004-1008. (Pubitemid 47135565)
22. Wysokinski WE, Ammash N, Sobande F, Kalsi H, Hodge D, McBane RD. Predicting left atrial thrombi in atrial fibrillation. Am Heart J. 2010;159:665-671.
23. Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo, J Am Coll Cardiol. 1994;23:961-969. (Pubitemid 24090884)
24. Oh JK, Seward JB, Tajik AJ. The Echo Manual, 3rd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 1994:109-119.
25. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285:2864-2870. (Pubitemid 32537350)
26. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160.
27. Gillum RF, Fortmann SP, Prineas RJ, Kottke TE. International diagnostic criteria for acute myocardial infarction and acute stroke. Am Heart J. 1984;108:150-158. (Pubitemid 14087982)
28. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Circulation. 2006;15:114:e257-e354.
29. Salem RO, Van Cott EMA. New automated screening assay for the diagnosis of von Willebrand disease. Am J Clin Pathol. 2007;127: 730-735.
30. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129:93-100. (Pubitemid 40524057)
31. Pruthi RK, Daniels TM, Heit JA, Chen D, Owen WG, Nichols WL. Plasma von Willebrand factor multimer quantitative analysis by in-gel immunostaining and infrared fluorescent imaging. Thromb Res. 2010; 126:543-549.
32. Rastegar R, Harnick DJ, Weidemann P, Fuster V, Coller B, Badimon JJ, Chesebro J, Goldman ME. Spontaneous echo contrast videodensity is flow-related and is dependent on the relative concentrations of fibrinogen and red blood cells. J Am Coll Cardiol. 2003;41:603-610. (Pubitemid 36223326)
33. Hart RG, Pearce LA, Miller VT, Anderson DC, Rothrock JF, Albers GW, Nasco E. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis. 2000;10:39-43. (Pubitemid 30034856)
34. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood. 1996;88:2939-2950. (Pubitemid 26357374)
35. Lip GY, Lane D, Van Walraven C, Hart RG. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke. 2006;37:2294-2300; (Pubitemid 44337172)
36. Erratum in: Stroke. 2006;37:2444.
37. Heppell RM, Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart. 1997;77:407-411. (Pubitemid 27278416)
38. Kumagai K, Fukuchi M, Ohta J, Baba S, Oda K, Akimoto H, Kagaya Y, Watanabe J, Tabayashi K, Shirato K. Expression of the von Willebrand factor in atrial endocardium is increased in atrial fibrillation depending on the extent of structural remodeling. Circ J. 2004;68:321-327. (Pubitemid 38470705)
39. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397. (Pubitemid 38419992)